

# Virulence Factors Profile and Antimicrobial Resistance of *Acinetobacter baumannii* Strains Isolated from Various Infections Recovered from Immunosuppressive Patients

MOHAMMAD DARVISHI

Infectious Diseases and Tropical Medicine Research Center (IDTMRC),  
AJA University of Medical Sciences, Tehran, Iran.

\*Corresponding author Email: mohammaddarvishi@gmail.com

<http://dx.doi.org/10.13005/bpj/1048>

(Received: December 10, 2016; accepted: December 19, 2016)

## ABSTRACT

Natural inherent of *Acinetobacter baumannii* to survive in hard conditions in surfaces and its ability to resist against commonly used antibiotics in hospitals caused it to be one of the most prevalent cause of hospital infections. The present study was carried out to research the prevalence, antibiotic resistance pattern and distribution of virulence genes in the *A. baumannii* strains of various infections of immunosuppressive patients. One-hundred and fifty samples were collected and cultured. Their positive results were subjected to disk diffusion and PCR. Of all 150 samples studied, 20 samples (13.33%) were infected with *A. baumannii*. Wound infections had the highest prevalence of *A. baumannii* (16%). *CsgA* (70%) and *cnf1* (50%) were the most commonly detected virulence genes. *A. baumannii* strains showed the highest levels of resistance against ampicillin (100%), tetracycline (95%), gentamycin (75%) and cephalexin (60%), while lowest against imipenem (5%) and ceftriaxone (35%). Statistically significant difference was seen between the type of samples and prevalence of *A. baumannii*, prevalence of antibiotic resistance and also distribution of virulence genes ( $P < 0.05$ ). Quick determination of infections caused by *A. baumannii* and its treatment with imipenem can decrease the risk of *A. baumannii*'s infections.

**Keywords:** *Acinetobacter baumannii*, Virulence genes, Antibiotic resistance pattern, Immunosuppressive patients, Clinical infections.

## INTRODUCTION

Healthcare-associated and hospital-acquired infections (HAIs) are common cause of mortality and morbidity all-around the world. Pathogenic bacteria are the most important causes of HAIs. Among all of the, *Acinetobacter baumannii* is one of the most prevalent cause of infections in the hospital environment<sup>1,2</sup>.

*Acinetobacter* species are aerobic gram-negative bacilli that can survive for prolonged periods in the environment and on the hands of healthcare workers<sup>1,3</sup>. Furthermore, *Acinetobacter* infections have become increasingly difficult to treat because of the emergence of strains resistant to

various types of antibiotics including cephalosporins, quinolones, sulfonamides, macrolides, aminoglycosides, fluoroquinolones and tetracycline<sup>4,5</sup>. These multidrug-resistant (MDR) strains are responsible for causing various types of infections including endocarditis, wound, skin and soft tissue infections, meningitis, septicemia, pneumonia and respiratory and urinary tract infections (RI and UTIs)<sup>1,3</sup>.

Pathogenesis of diseases caused by *A. baumannii* is derived from the presence of latent virulence genes<sup>6,7</sup>. Some of the most significant virulence genes of the *A. baumannii* strains of human clinical infections are colicin V production (*cvaC*), curli fibers (*csg*), siderophores like

aerobactin (*iutA*) and cytotoxic necrotizing factor (*cnf*)<sup>6,7</sup>. Detection of latent virulence genes in the clinical isolates of *A. baumannii* has some great epidemiological outcomes help practitioners to control dissemination of infectious diseases caused by this bacterium.

Up to now, there were no well-conducted previously published data about the prevalence and epidemiology of *A. baumannii* strains in human clinical samples in Iran. Therefore, the present investigation was done in order to study the prevalence, distribution of virulence genes and antibiotic resistance pattern of *A. baumannii* strains isolated from various types of infections recovered from immunosuppressive hospitalized patients.

## MATERIALS AND METHODS

### Samples and *Acinetobacter baumannii* isolation

From January 2015 to April 2016, a total of 150 infectious samples including wound (n=50), respiratory (n=40) and urine (n=60) samples were collected from immunosuppressive patients hospitalized in hospitals and health care centers of Iran. Samples were collected from less than 70 years old hospitalized patients. Samples were immediately transferred to the laboratory in cooler with ice packs.

Samples were inoculated on to blood agar (Merck, Germany) and MacConkey agar (Merck, Germany) and incubated aerobically at 37°C for

**Table 1: Primer sequence and PCR conditions used for detection of virulence genes in the *A. baumannii* isolates of various types of infections**

Gene target	Primer sequence (5'-3')	PCR product (bp)	PCR Volume (50µL)	PCR programs
<i>cnf1</i>	F: AAGATGGAGTTTCCTATGCAGGAG	498	5µL PCR buffer 10X	1 cycle:95 °C — 4 min.30
	R: CATTGAGAGTCCTGCCCTCATTATT			
<i>csgA</i>	F: ACTCTGACTTGACTATTACC	200	1.5 mM MgCl <sub>2</sub> 200 µM dNTP (Fermentas)0.5 µM of each primers F & R	cycle:95 °C — 50 s
	R:AGATGCAGTCTGGTCAAC			
<i>cvaC</i>	F:CACACACAAACGGGAGCTGTT R: CTTCCCGCAGCATAGTTCCAT	680	1.25 U Taq DNA polymerase (Fermentas)	58 °C — 60 s72 °C — 45 s
<i>iutA</i>	F:GGCTGGACATCATGGGAACTGG R:CGTCGGGAACGGGTAGAATCG	300	2.5 µL DNA template	72 °C — 1 cycle: 8 min

24 hours. Non-hemolytic, opaque and creamy colonies on blood agar and nonlactose fermenting colonies on MacConkey agar were further sub-cultured on MacConkey agar and incubated for another 24 hours at 37°C to obtain pure colonies. The isolated organisms were identified based on colonial and microscopic characteristics and various biochemical tests according to standard laboratory methods<sup>8</sup>. Further identification of isolates was done using Gram stain, oxidase test and API 20NE identification strip (Biomérieux, Marcy l'Etoile, France).

**Table 2: Total distribution of *A. baumannii* isolates of various types of infections**

Type of samples	No. samples collected	Prevalence of <i>A. baumannii</i> (%)
Wound	50	8 (16)
Urine	60	7 (11.66)
Respiratory	40	5 (12.50)
Total	15	20 (13.33)

**Antimicrobial susceptibility testing**

Pattern of antimicrobial resistance was studied using the simple disk diffusion technique. The Mueller–Hinton agar (Merck, Germany) medium was used for this purpose. Antibiotic resistance of *A. baumannii* strains against commonly used antibiotics was determined using the instruction of Clinical and Laboratory Standards Institute guidelines<sup>9</sup>. Susceptibility of *A. baumannii* strains were tested against levofloxacin (5 µg/disk), ampicillin (10 u/disk), imipenem (30 u/disk), gentamycin (10 µg/disk), cephalothin (30 µg/disk), cephalexin (10 µg/disk), tetracycline (30 µg/disk), trimethoprim/sulfamethoxazole (25 µg/disk) and ceftriaxone (30 µg/disk) antibiotic agents (Oxoid, UK). All of the inoculated plates were aerobically incubated at 37 °C for 18-24 h in an aerobic atmosphere. Results were interpreted based on the instruction provided by CLSI (2012) (9). In all reactions, the *A. baumannii* ATCC 19605 was used as quality control bacterium.

**DNA extraction from the *Acinetobacter baumannii* isolates**

A single colony of *A. baumannii* was inoculated on 5 ml of nutrient broth and incubated over night at 37 °C. Genomic DNA was extracted from the bacterial colony using the genomic DNA extraction kit (Fermentas, Germany) according to the manufacture instruction. The DNA concentration has been determined by measuring absorbance of the sample at 260 nm using spectrophotometer<sup>10</sup>.

**PCR-based detection of virulence genes**

Table 1 indicates list of primers and PCR program used for detection of virulence factors (11). The DNA was amplified in a programmable thermal cycler (Eppendorf, Mastercycler® 5330, Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany). Fifteen microliters of PCR products were resolved on a 1.5% agarose gel containing 0.5 mg/ml of SYBR Green in Tris–borate–EDTA buffer at 90 V for 40 min, also using suitable molecular weight markers.

**Table 3. Total distribution of putative virulence genes among the *A. baumannii* isolates of various types of infections**

Type of samples (no positive)	Distribution of virulence genes (%)			
	<i>Cnf1</i>	<i>CsgA</i>	<i>CvaC</i>	<i>lutA</i>
Wound (8)	4 (50)	4 (50)	1 (12.50)	1 (12.50)
Urine (7)	3 (42.85)	5 (71.42)	-	1 (14.28)
Respiratory (5)	3 (60)	5 (100)	1 (20)	3 (60)
Total (20)	10 (50)	14 (70)	2 (10)	5 (25)

**Table 4: Antibiotic resistance pattern of the *A. baumannii* isolates of various types of infections.**

Type of samples (no positive)	Antibiotic resistance pattern (%)								
	Lev *	Amp	Imp	Gen	Ceph	Cphx	Tet	Tr-Su	Ceft
Wound (8)	3 (37.50)	8 (100)	1 (12.50)	8 (100)	3 (37.50)	4 (50)	8 (100)	4 (50)	2 (37.50)
Urine (7)	4 (57.14)	7 (100)	-	3 (42.85)	3 (42.85)	5 (71.42)	7 (100)	4 (57.14)	3 (42.85)
Respiratory (5)	3 (60)	5 (100)	-	4 (80)	2 (40)	3 (60)	4 (80)	3 (60)	2 (40)
Total (20)	10 (50)	20 (100)	1 (5)	15 (75)	8 (40)	12 (60)	19 (95)	11 (55)	7 (35)

The products were examined under ultraviolet illumination. *A. baumannii* ATCC 17978 and *A. baumannii* ATCC 19606 and rough strains purchased from the Pasteur Institute (Tehran, Iran) were used as positive controls and distilled water (D.W, Merck, Germany) was used as a negative control.

### Statistical analysis

Statistical analysis was performed using SPSS/21.0 software (SPSS Inc., Chicago, IL). The chi-square test and Fisher's exact 2-tailed test analysis were performed in this study. Statistical significance was regarded at a  $P$  value  $< 0.05$ .

## RESULTS

Table 2 represents the distribution of *A. baumannii* isolates of various types of infections. Twenty out of 150 samples (13.33%) were infected with *A. baumannii*. Wound infections had the highest prevalence of *A. baumannii* (16%), while urine had the lowest (11.66%). Statistically significant difference was seen between the type of samples and prevalence of *A. baumannii* ( $P < 0.05$ ).


Figure 1 represents the results of the gel electrophoresis for detection of the virulence genes of the *A. baumannii* isolates of various types of infections. Table 3 shows the distribution of putative virulence genes among the *A. baumannii* strains of various types of infections. Results showed that

bacterial strains of respiratory infections had the highest and also most variable profile of the virulence genes. Totally, *csgA* (70%) and *cnf1* (50%) were the most commonly detected virulence genes. Statistically significant difference was seen between the type of samples and prevalence of virulence genes ( $P < 0.05$ ).

Table 4 indicates the pattern of antibiotic resistance of the *A. baumannii* isolates of various types of infections. *A. baumannii* strains of our study harbored the highest levels of resistance against ampicillin (100%), tetracycline (95%), gentamycin (75%) and cephalexin (60%). Prevalence of resistance against imipenem (5%) and ceftriaxone (35%) were low. Statistically significant difference was seen between the type of samples and prevalence of antibiotic resistance ( $P < 0.05$ ).

## DISCUSSION

Resistant and virulent strains of *A. baumannii* had a high prevalence in various types of human clinical infectious samples of immunosuppressive patients of our study. Totally, 13.33% of samples were infected with *A. baumannii* which was considerable. Some of the most common reasons for the high prevalence of resistant and virulent strains of *A. baumannii* in our study are indiscriminate and unauthorized prescription of antibiotics, daydreaming to the results obtained from the disk diffusion method, prescription of antibiotics



**Fig. 1:** Results of the gel electrophoresis for detection of the virulence genes of the *A. baumannii* isolates of various types of infections. M: 100 bp ladder (Fermentas, Germany), 1, 2: Positive sample for the *csgA* gene and its positive control, respectively, 3, 4: Positive sample for the *iutA* gene and its positive control, respectively, 5, 6: Positive sample for the *cnf1* gene and its positive control, respectively, 7, 8: Positive sample for the *cvaC* gene and its positive control, respectively, and 9: Negative control.

based on the self-experience of medical practitioners, lack of proper disinfection of hospital environment, inherent nature of the bacteria that has the ability to withstand hard conditions and can survive in the surfaces and finally transmission of resistant pathogens from infected patients and workers to hospital environment and also other patients. Momtaz et al. (2015)<sup>11</sup> reported that *A. baumannii* strains were detected in 121 out of 500 human clinical samples (24.2%) which was higher than our results. Jaggi et al. (2012) (12) reported that the prevalence of *A. baumannii* in various types of clinical infections were 9.4% which was lower than our results. Siau et al. (1996)<sup>13</sup> reported that the prevalence of *A. baumannii* in the cases of infections in the Korean hospitals was 11% which was lower than our results. Differences in the type of samples, method of sampling, number of samples collected, method of experiment, sex and age of patients and geographical area which the samples were collected are the main factors for differences in the prevalence of *A. baumannii* in various investigations.

We found that bacterial strains had the high levels of resistance against ampicillin, imipenem, gentamycin, cephalexin, tetracycline and trimethoprim/sulfamethoxazole antibiotics which showed indiscriminate and unauthorized prescription of antibiotics. Management of multidrug-resistant *A. baumannii* infections is a countless challenge for medical practitioners and clinical microbiologists. Moradi et al. (2015)<sup>14</sup> showed that *A. baumannii* strains of human clinical infections had a high prevalence of resistance against all types of antibiotics, with the exception of carbapenems, lipopeptides, and aminoglycosides. Jaggi et al. (2012)<sup>12</sup> reported that the prevalence of antibiotic resistance in the *A. baumannii* strains of clinical samples against amikacin, gentamicin, tobramycin, aztreonem, cefipime, ceftazidime, ciprofloxacin, Levofloxacin and imipenem were

90.3%, 85.8%, 80%, 94.2%, 90.3%, 92.1%, 67.4% and 67.1%, respectively which was similar to our results. Similar findings have been reported from Denmark<sup>15</sup>, Iran<sup>16</sup>, Colombia<sup>17</sup> and China<sup>18</sup>,

*Csga*, *cnf1*, *cvaC* and *iutA* virulence genes had a considerable prevalence among the *A. baumannii* strains of our clinical infections. Daryanavard and Safaei (2015) (19) reported that the total prevalence of *csga*, *cnf1*, *cvaC* and *iutA* virulence genes among the samples of UTIs were 55%, 40%, 10% and 30%, respectively which was similar to our findings. Momtaz et al. (2015)<sup>11</sup> reported that the prevalence of *csga*, *cnf1*, *cvaC* and *iutA* virulence genes among the *A. baumannii* strains of clinical infections in Iran were 12.39%, 35.53%, 21.48% and 19%, respectively which was lower than our results. Mohajeri et al. (2016)<sup>20</sup> showed that 40 isolates of *A. baumannii* strains of clinical infections had *traT* (80%), 17 isolates had *cvaC* (34%) and 8 isolates had *iutA* (16%) genes. These genes are the most common causes of adhesion and invasion of *A. baumannii* to the epithelial cells of the human organs.

## CONCLUSIONS

In conclusion, we identified a large number of resistant and virulent strains of *A. baumannii* in the wound, urinary and respiratory infections of immunosuppressive patients hospitalized in Iranian hospitals and health care centers. Totally, respiratory infections had the highest prevalence of bacteria and also *csga* and *cnf1* were the most commonly detected virulence genes. We found that resistance against ampicillin, tetracycline and gentamycin was maximum. Rapid diagnosis of infections caused by *A. baumannii* and its treatment with imipenem and ceftriaxone can reduce the risk of dissemination of *A. baumannii*'s infections. Judicious prescription of antibiotics according to the results of disk diffusion method can help to decrease prevalence of resistance.

## REFERENCES

1. Wspringhoff H, Seifert H. Epidemiology and clinical features of *Acinetobacter baumannii* infections in human. *Berl Munch Tierarztl Wochenschr*; 127(11-12):447-57 (2014 Nov-Dec).
2. Alsan M<sup>1</sup>, Klompas M<sup>1</sup>. *Acinetobacter baumannii*: An Emerging and Important Pathogen. *J Clin Outcomes Manag*;

- 17(8):363-369 (2010 Aug).
3. Al-Anazi KA<sup>1</sup>, Al-Jasser AM<sup>2</sup>. Infections Caused by *Acinetobacter baumannii* in Recipients of Hematopoietic Stem Cell Transplantation. *Front Oncol*. **14**;4:186 (2014 Jul).
  4. Gordon NC<sup>1</sup>, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. *Int J Antimicrob Agents*; **35**(3):219-26 (2010 Mar).
  5. Lin MF<sup>1</sup>, Lan CY<sup>1</sup>. Antimicrobial resistance in *Acinetobacter baumannii*: From bench to bedside. *World J Clin Cases*; **2**(12):787-814.
  6. Erač B<sup>1</sup>, Yılmaz FF, Hoğör Limoncu M, Oztürk I, Aydemir S. Investigation of the virulence factors of multidrug-resistant *Acinetobacter baumannii* isolates. *Mikrobiyol Bul*; **48**(1):70-81 (2014 Jan).
  7. Eijkelkamp BA, Stroehler UH, Hassan KA, Paulsen IT, Brown MH<sup>1</sup>. Comparative analysis of surface-exposed virulence factors of *Acinetobacter baumannii*. *BMC Genomics* **25**;15:1020 (2014 Nov).
  8. Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. *J Trauma*; **64**(2):163-68 (2008).
  9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. M100-S21. Wayne Pa: CLSI; (2012).
  10. Sambrook J, Russell D. Molecular cloning, a laboratory manual. In *Cold Spring Harbor Laboratory*. 3rd edition. Cold Spring Harbor, NY; (2001).
  11. Momtaz H, Seifati SM, Tavakol M. Determining the prevalence and detection of the most prevalent virulence genes in *Acinetobacter Baumannii* Isolated from hospital Infections. *International Journal of Medical Laboratory*; **2**(2): 87-97 (2015).
  12. Jaggi N, Sissodia P, Sharma L. *Acinetobacter baumannii* isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. *J Microbiol Infect Dis*, **12**: 57-63 (2012).
  13. Siau H, Yuen KY, Wong SSS, Ho PL, Luk WK. The epidemiology of *Acinetobacter* infections in Hong Kong. *J. Med. Microbiol.*-Vol.**44**, 340-347 (1996).
  14. Moradi J, Hashemi FB, Bahador A. Antibiotic Resistance of *Acinetobacter baumannii* in Iran: A Systemic Review of the Published Literature. *Osong Public Health Res Perspect*; **6**(2): 79–86 (2015 Apr).
  15. Văduva DB<sup>1</sup>, Muntean D, Lonescu G, Licker M, Văduva MB, Velimirovici D, Rădulescu M, Dumitra<sup>o</sup>cu V, Crăciunescu M, Dugăe<sup>o</sup>escu D, Horhat F, Piluș C, Bădișoiu L, Moldovan R. Antibiotic resistance patterns in *Acinetobacter* spp. strains isolated from hospital environment. *Bacteriol Virusol Parazitol Epidemiol*; **53**(2):103-7 Apr-Jun (2008).
  16. Mirnejad R, Vafaei S. Antibiotic resistance patterns and the prevalence of ESBLs among strains of *Acinetobacter baumannii* isolated from clinical specimens. *Journal of Genes, Microbes and Immunity*; 1-8 (2013).
  17. Reguero MT<sup>1</sup>, Medina OE, Hernández MA, Flórez DV, Valenzuela EM, Mantilla JR. Antibiotic resistance patterns of *Acinetobacter calcoaceticus*-A. *baumannii* complex species from Colombian hospitals. *Enferm Infecc Microbiol Clin*; **31**(3):142-6.
  18. Zhao S, Jiang D, Xu P, Zhang Y, Shi H, Cao H, Wu Q. An investigation of drug-resistant *Acinetobacter baumannii* infections in a comprehensive hospital of East China. *Ann Clin Microbiol Antimicrob*; **14**: 7 (2015).
  19. Daryanavard R, Safaei HR. Virulence genes and antimicrobial resistance properties of *Acinetobacter baumannii* isolated from pediatrics suffered from UTIs. *Int. J. Adv. Res. Biol. Sci.* **2**(11): 272–279 (2015).
  20. Mohajeri P, Sharbati S, Farahani A, Rezaei Z. Evaluate the frequency distribution of nonadhesive virulence factors in carbapenemase-producing *Acinetobacter baumannii* isolated from clinical samples in Kermanshah. *J Nat Sci Biol Med*; **7**(1):58-61 (2016 Jan-Jun).